Register for our S/EIS Fund

We launched our first “o2h Kickstarter competition” back in August 2022 exclusively for early-stage biotech to boost their drug discovery research. TJoin us as we discuss how this competition supported their research and development efforts.

The Panelists
Dr Janette Thomas CEO

Janette has a background in biochemistry research at Leicester, Cambridge, and Glaxo, after which she has had 30 years of pharmaceutical drug discovery and development experience from large Pharma (GSK) and SMEs. She has been instrumental in the early strategy and growth of small companies, including Horizon Discovery (now a public company). She was Director of International Operations at Atlantic Healthcare until she founded Pellis Care Ltd.

Vid Stojevic CEO

Vid Stojevic is an expert in theoretical physics, quantum physics, tensor networks, string theory, machine learning and mathematical modelling with over 15 years of postdoctoral experience at leading centres including the University of Hamburg, University of Vienna, University of Ghent and University College London. Vid founded his first AI biotech under the Entrepreneur First program and has 5 years of experience leading AI/ML start-ups. Vid holds a PhD in theoretical physics from King’s College London.

Neil Benson CEO

Neil has more than 25 years’ of experience in the application of mathematical modelling to Drug Discovery. He has held various senior leader roles including Translational PKPD lead for the Pain Therapeutic area at Pfizer, Head of Systems Pharmacology Pfizer, Founder and CEO at Xenologiq Limited and Head Of Operations at Certara QSP. Neil is currently a consultant in PKPD and QSP modelling and CEO of Sevenless Therapeutics.

Beth J Hoffman President and CEO

Beth brings more than 25 years of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain and psychiatry. Prior to Origami, she was Vice President, Discovery Biology for Vertex Pharmaceuticals.

Jason Rutt CEO

Jason has a degree and PhD in Chemistry from Imperial College and Nottingham University. After leaving research he qualified as a UK and European Patent Attorney, going on to become Head of Pfizer’s UK Patent Dept and member of Site Management team. Before founding Azadyne, Jason worked with a number of UK biotech start-ups.

Sunil Shah CEO (moderator)

Sunil Shah is a serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.

Register for Invitations